Straits Times Index
3,090.20 -20.53 (-0.66%) S&P 500
4,617.41 +13.04 (+0.28%) Dow
36,376.96 +129.09 (+0.36%) Nasdaq
14,416.62 +12.65 (+0.09%) Bitcoin USD
40,687.81 -3,206.16 (-7.30%) CMC Crypto 200
838.27 -76.54 (-8.37%)
AZN Jan 2024 60.000 put
| Previous close | 0.5200 |
| Open | 0.4700 |
| Bid | 0.5000 |
| Ask | 0.5300 |
| Strike | 60.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.4700 - 0.4700 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.35k |
Yahoo FinanceNovo Nordisk's unique structure gives it an extra edge — and risk
Novo Nordisk's corporate structure has a few quirks that investors need to know about.
Business WireLong-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
WILMINGTON, Del., December 11, 2023--Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) continued to demonstrate clinical benefit for patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH).1
Motley FoolAstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge their drug development efforts -- and AstraZeneca's (NASDAQ: AZN) materials are no different. Let's probe this issue by looking at the collaboration and acquisition activity that the company is pursuing. It's no surprise that drugmakers are interested in using AI to accelerate the pace of drug development.
